Coherus BioSciences (CHRS) Tops Q2 EPS by 14c, beats revenue
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.13 --0%
Revenue Growth %: +37.8%
Financial Fact:
Cost of goods sold: 219.53M
Today's EPS Names:
OCCI, PMCB, BRID, More
Revenue Growth %: +37.8%
Financial Fact:
Cost of goods sold: 219.53M
Today's EPS Names:
OCCI, PMCB, BRID, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.49), $0.14 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $58.7 million versus the consensus estimate of $50.47 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
- Rothschild Redburn Reiterates Buy Rating on Nu Holdings (Nubank) (NU)
- JPMorgan Reiterates Overweight Rating on Rexel SA (RXL:FP) (RXLSF)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
